Read by QxMD icon Read

Journal of Comparative Effectiveness Research

Richard White
No abstract text is available yet for this article.
October 19, 2016: Journal of Comparative Effectiveness Research
Stephanie R Morain, Thomas W Concannon, Eve Wittenberg
Substantially engaging stakeholders in research involves making extensive changes to the full life cycle of research, from the initial stage of selecting research priorities to the final stages of dissemination and implementation. Recent scholarship has explored logistical and methodological challenges, including the time, training and resources required for engagement. However, inadequate attention has been given to the intended ends or goals of engagement - what do we want engagement to achieve? An examination of historical case studies can yield important insights regarding engagement and its intended ends...
September 2, 2016: Journal of Comparative Effectiveness Research
Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Francisco de Assis Acurcio, Haliton Alves de Oliveira Junior, Adriana Maria Kakehasi, Augusto Afonso Guerra Junior, Marion Bennie, Brian Godman, Juliana Alvares
AIM: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil. This open prospective cohort study evaluated their effectiveness and safety among RA patients in the Brazilian Public Health System given their costs. METHODS: The Clinical Disease Activity Index was primarily used to assess their effectiveness after 6 and 12 months of follow-up. The Health Assessment Questionnaire and EuroQol-5D were also used...
November 2016: Journal of Comparative Effectiveness Research
Jonathan Alsop, Martin Scott, William Archey
Clinical trial designs often fail to deliver data that jointly satisfy evolving demands of both regulatory and reimbursement authorities. We propose a new multi-tiered trial design to integrate efficacy and effectiveness, and address the evolving needs of authorities. The mixed randomized trial allocates patients first to trial arm - randomized controlled, pragmatic (randomized) or observational - and then to treatment group - experimental, placebo, active comparator, best available therapy or standard of care...
November 2016: Journal of Comparative Effectiveness Research
Robert W Dubois
No abstract text is available yet for this article.
November 2016: Journal of Comparative Effectiveness Research
Mattias Neyt, Thierry Christiaens, Jacques Demotes, Tom Walley, Frank Hulstaert
AIM: Many questions of relevance to patients/society are not answered by industry-sponsored clinical trials. We consider whether there are benefits to governments in funding practice-oriented clinical trials. METHODOLOGY: A literature search including publications on institutions' websites was performed and supplemented with information gathered from (inter)national stakeholders. RESULTS: Areas were identified where public funding of clinical trials is of importance for society, such as head-to-head comparisons or medical areas where companies have no motivation to invest...
November 2016: Journal of Comparative Effectiveness Research
Roxanne E Jensen, Claire F Snyder, Ethan Basch, Lori Frank, Albert W Wu
In recent years, patient-reported outcomes have become increasingly collected and integrated into electronic health records. However, there are few cross-cutting recommendations and limited guidance available in this rapidly developing research area. Our goal is to report key findings from a 2013 Patient-Centered Outcomes Research Institute workshop on this topic and a summary of actions that followed from the workshop, and present resulting recommendations that address patient, clinical and research/quality improvement barriers to regular use...
November 2016: Journal of Comparative Effectiveness Research
Daniel E Jonas, Diego Garza
No abstract text is available yet for this article.
November 2016: Journal of Comparative Effectiveness Research
Nadeem Ahmed, Jaclyn Carberry, Vannesa Teng, David Carrick, Colin Berry
ST-elevation myocardial infarction (STEMI) is one of the leading causes of mortality and morbidity worldwide. While the survival after acute STEMI has considerably improved, mortality rate still remains high, especially in high-risk patients. Survival after acute STEMI is influenced by clinical characteristics such as age as well as the presence of comorbidities. However, during emergency care increasing access to tools such as the electrocardiogram, chest x-ray and echocardiography can provide additional information helping to further risk stratify patients...
November 2016: Journal of Comparative Effectiveness Research
Craig T Hartrick, Jeffrey Abraham, Li Ding
AIM: To compare the ease-of-care (EOC) examining time efficiency, convenience and satisfaction of fentanyl iontophoretic transdermal system ([ITS] IONSYS(®)) and morphine intravenous patient-controlled analgesia (iv. PCA) in postoperative pain management using a validated physical therapist (PT) EOC questionnaire. MATERIALS & METHODS: This meta-analysis assessed EOC of fentanyl ITS versus morphine iv. PCA using data from two randomized, active-comparator studies (fentanyl ITS: n = 720 and morphine iv...
November 2016: Journal of Comparative Effectiveness Research
Nima Kokabi, Minzhi Xing, Richard Duszak, David H Howard, Juan C Camacho, Hyun S Kim
AIM: To investigate national practice trends in the use of surgical resection (SX) versus thermal ablation (TA) for the management of T1aN0M0 renal cell carcinoma with regard to sociodemographic factors and associated outcomes. MATERIALS & METHODS: Patients diagnosed in 2004-2011 were identified using the Surveillance, Epidemiology and End Results registry. Sociodemographic factors predicting the use of surgery versus TA were determined using logistic regression...
August 2016: Journal of Comparative Effectiveness Research
Ian Porter, Daniela Gonçalves-Bradley, Ignacio Ricci-Cabello, Chris Gibbons, Jaheeda Gangannagaripalli, Ray Fitzpatrick, Nick Black, Joanne Greenhalgh, Jose M Valderas
Patient-reported outcomes (PROs) are reports of the status of a patient's health condition that come directly from the patient. While PRO measures are a well-developed technology with robust standards in research, their use for informing healthcare decisions is still poorly understood. We review relevant examples of their application in the provision of healthcare and examine the challenges associated with implementing PROs in clinical settings. We evaluate evidence for their use and examine barriers to their uptake, and present an evidence-based framework for the successful implementation of PROs in clinical practice...
August 2016: Journal of Comparative Effectiveness Research
Tully Saunders, Thomas I Mackie, Supriya Shah, Holly Gooding, Sarah D de Ferranti, Laurel K Leslie
AIM: Explore perspectives of adolescent and young adult (AYA) and parent stakeholders regarding their engagement in comparative effectiveness research (CER) evaluating cholesterol screening and treatment strategies for 17-21 year olds. METHODS: All nine AYAs and parent stakeholders participating in a 20-member panel of AYAs, parents and professionals (i.e., clinicians, researchers, policy makers, payers), completed a quantitative survey and a semistructured interview at the completion of the core CER study...
August 2016: Journal of Comparative Effectiveness Research
Vishal Bali, Satabdi Chatterjee, Michael L Johnson, Hua Chen, Ryan M Carnahan, Rajender R Aparasu
AIM: To evaluate comparative safety of paroxetine and other selective serotonin reuptake inhibitors (SSRIs) for the risk of hip fractures. PATIENTS & METHODS: A propensity score-matched retrospective cohort study was conducted using 2007-2010 Minimum Data Set linked Medicare data. Robust Cox proportional hazards model was used to evaluate the risk of hip fractures in depressed elderly nursing home residents. RESULTS: Cox analysis did not find any significant difference in the risk of hip fractures for the paroxetine users (hazard ratio: 1...
August 2016: Journal of Comparative Effectiveness Research
Asher J Steene
No abstract text is available yet for this article.
August 2016: Journal of Comparative Effectiveness Research
Ram Subramanian, Kevin Schorr
No abstract text is available yet for this article.
August 2016: Journal of Comparative Effectiveness Research
Rachel Topazian, Juli Bollinger, Kevin P Weinfurt, Rachel Dvoskin, Debra Mathews, Kathleen Brelsford, Matthew DeCamp, Jeremy Sugarman
AIM: Practicing physicians inevitably become involved in pragmatic clinical trials (PCTs), including comparative effectiveness research. We sought to identify physicians' perspectives related to PCTs. METHODS: In-depth semistructured interviews with 20 physicians in the USA. RESULTS: Although physicians are generally willing to participate in PCTs, their support is predicated on several factors including expected benefits, minimization of time and workflow burdens and physician engagement...
August 2016: Journal of Comparative Effectiveness Research
Nazish Saleem, Brian Godman, Shahzad Hussain
BACKGROUND: Gestational diabetes mellitus is a common medical problem associated with maternal and fetal complications. Good glycemic control is the cornerstone of treatment. OBJECTIVE: Compare outcomes between four times (q.i.d) and twice daily (b.i.d) regimens. The morning dose of the b.i.d regimen contained two-thirds of the total insulin, comprising a third human regular insulin and two-thirds human intermediate insulin; equal amounts in the evening. METHODS: 480 women at >30 weeks with gestational diabetes mellitus with failure to control blood glucose were randomly assigned to either regimen...
August 2016: Journal of Comparative Effectiveness Research
Sándor Szántó, Gyula Poór, Daniela Opris, Oleg Iaremenko, Leona Procházková, Reet Kuuse, Orsolya Nagy, Valentyn Chernyshov, Pál Géher
AIM: Adalimumab effectiveness on clinical, functional and work-related outcomes was evaluated in patients with active ankylosing spondylitis or psoriatic arthritis treated in routine clinical practice in central-eastern Europe. METHODS: Patients (n = 555) were followed for 12 months. Primary end point was percentage of patients with a treatment response (≥50% decrease from baseline in Bath Ankylosing Spondylitis Disease Activity Index or ≥1.2 point decrease from baseline in Disease Activity Index-28 joint for axial or peripheral symptoms, respectively)...
August 2016: Journal of Comparative Effectiveness Research
Yunyu Huang, Jaco Voorham, Flora M Haaijer-Ruskamp
AIM: Details of data quality and how quality issues were solved have not been reported in published comparative effectiveness studies using electronic health record data. METHODS: We developed a conceptual framework of data quality assessment and preprocessing and apply it to a study comparing angiotensin-converting enzyme inhibitors with angiotensin receptor blockerss on renal function decline in diabetes patients. RESULTS: The framework establishes a line of thought to identify and act on data issues...
July 2016: Journal of Comparative Effectiveness Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"